Skip to main content
CONTEC MEDICAL SYSTEMS CO., LTD. logo

CONTEC MEDICAL SYSTEMS CO., LTD. — Investor Relations & Filings

Ticker · 300869 ISIN · CNE1000047F0 LEI · 6556007SL3V6YKCWVA55 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2024-05-14 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300869

About CONTEC MEDICAL SYSTEMS CO., LTD.

https://www.contecmed.com.cn

CONTEC Medical Systems Co., Ltd. focuses on the research, development, manufacturing, and distribution of medical electronic instruments. The product portfolio encompasses a wide range of diagnostic and monitoring solutions, including pulse oximeters, blood pressure monitors, electrocardiographs, ultrasound equipment, and multi-parameter patient monitors. Additionally, the company provides specialized devices such as fetal monitors, sleep apnea screening systems, and biochemical analyzers. By leveraging integrated research and large-scale production facilities, the organization delivers medical technology designed for clinical, hospital, and home healthcare environments. The company emphasizes technical innovation and adheres to international quality standards to ensure the precision and reliability of its medical hardware and software solutions.

Recent filings

Filing Released Lang Actions
关于举行2023年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the holding of the 2023 annual performance explanation meeting (业绩说明会) by 康泰医学系统(秦皇岛)股份有限公司. It mentions that the full 2023 annual report has already been published on April 25, 2024, and provides details about the upcoming investor conference call scheduled for May 17, 2024. The document invites investors to submit questions in advance and lists the attendees expected at the meeting. The document itself does not contain the annual report or detailed financial data but serves as a notice for the upcoming earnings call or performance explanation meeting. Given the content and length (853 characters), this fits best as a Call Transcript (CT) announcement or more precisely an Investor Presentation (IP) announcement. However, since it is announcing a performance explanation meeting (which is a form of investor presentation focusing on financials and company strategy), the best classification is Investor Presentation (IP).
2024-05-14 Chinese
中信建投证券股份有限公司关于公司首次公开发行股票并在创业板上市之保荐总结报告书
Regulatory Filings Classification · 95% confidence The document is titled as a "保荐总结报告书" which translates to "Sponsorship Summary Report" related to the initial public offering (IPO) and listing of 康泰医学系统（秦皇岛）股份有限公司 on the Shenzhen Stock Exchange. It details the sponsorship work, due diligence, continuous supervision, and compliance with regulatory requirements by the sponsoring securities firms. The document includes descriptions of the sponsor's responsibilities, changes in sponsors, regulatory communications, and evaluations of the company's compliance and disclosures. It does not contain financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a comprehensive report on the sponsorship and regulatory supervision activities related to the IPO and subsequent continuous supervision period. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory compliance and supervision report rather than a financial report or announcement of voting results, management changes, or capital updates. The document length is 4302 characters, which is substantial and contains detailed content, not a mere announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2024-05-09 Chinese
中信建投证券股份有限公司关于康泰医学系统（秦皇岛）股份有限公司2023年度跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2023年度跟踪报告' (2023 Annual Tracking Report) issued by a sponsoring institution (中信建投证券股份有限公司) regarding 康泰医学系统（秦皇岛）股份有限公司. It details the sponsor's review and supervision activities over the company for the year 2023, including information disclosure, internal controls, fundraising supervision, governance, and other compliance matters. The document is not a full annual report (10-K) or an earnings release but rather a monitoring and compliance report by the sponsor. It does not contain financial statements or detailed financial analysis but focuses on oversight and regulatory compliance. This type of document aligns best with the category of Regulatory Filings (RNS), as it is a regulatory compliance report and does not fit other more specific categories such as Annual Report or Management Reports. The document length is 2042 characters, relatively short, and it is a report itself, not an announcement of a report publication. Therefore, the classification is RNS with high confidence.
2024-05-09 Chinese
关于全资子公司产品获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (800 characters) from a company about its wholly-owned subsidiary receiving a medical device registration certificate from a regulatory authority. It includes details about the certificate, product, and impact on the company. There are no financial statements, no detailed financial data, no earnings or management discussion, and no mention of a report being attached or published. This is a regulatory announcement about a non-financial event related to product registration. It does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a governance, capital, or legal filing. The best fit is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-05-06 Chinese
关于公司医疗器械产品获得美国FDA批准函的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the FDA approval of certain medical devices. It contains no financial statements, no detailed financial data, no management discussion, or regulatory certifications. The document is short (719 characters) and serves as a public notice about product approval and its potential impact on sales. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial report. It is a regulatory announcement about product approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-05-06 Chinese
第四届董事会第九次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a board meeting resolution announcement from 康泰医学系统（秦皇岛）股份有限公司 regarding the approval of the company's 2024 first quarter report. It states that the board has reviewed and approved the quarterly report and that the detailed report is published separately on the regulatory website. The document itself does not contain the actual financial data or the full quarterly report but is an announcement of the board's approval and meeting details. The document length is short (795 characters), and it references the full quarterly report being available elsewhere. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an announcement related to the quarterly report approval, not the report itself.
2024-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.